Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 7:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 941 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Active Comparator 2 Clear all
Completed Phase 2 Interventional Results available

Evaluate the Safety and Efficacy of FG-3019 (Pamrevlumab) in Participants With Idiopathic Pulmonary Fibrosis (IPF)

NCT01890265
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Pamrevlumab, Placebo, Sub-Study: Pirfenidone, Sub-Study: Nintedanib
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
40 Years to 80 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
26
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2020 · Synced Oct 21, 2026, 7:59 PM EDT
Completed Phase 3 Interventional Results available

A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066

NCT01130493
View directory record Official record
Conditions
Parkinson's Disease
Interventions
IPX066, CLE
Drug
Lead sponsor
Impax Laboratories, LLC
Industry
Eligibility
30 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
12
States / cities
Fresno, California • Sunnyvale, California • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2019 · Synced Oct 21, 2026, 7:59 PM EDT
Completed Phase 2 Interventional Results available

A Placebo Controlled Safety and Efficacy Study of INT131 Besylate in Type 2 Diabetes, With an Active Comparator

NCT00631007
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
INT131 besylate, Pioglitazone HCl, Placebo
Drug
Lead sponsor
InteKrin Therapeutics, Inc.
Industry
Eligibility
30 Years to 75 Years
Enrollment
367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
59
States / cities
Carmichael, California • Los Angeles, California • San Diego, California + 48 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2010 · Synced Oct 21, 2026, 7:59 PM EDT
Completed Phase 2 Interventional Results available

Lucinactant for Treatment of Acute Hypoxemic Respiratory Failure in Children up to Two Years Old

NCT00578734
View directory record Official record
Conditions
Acute Hypoxemic Respiratory Failure
Interventions
Lucinactant, Sham Comparator
Drug · Other
Lead sponsor
Windtree Therapeutics
Industry
Eligibility
Up to 2 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Warrington, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 3, 2012 · Synced Oct 21, 2026, 7:59 PM EDT
Recruiting Phase 3 Interventional

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

NCT06103864
View directory record Official record
Conditions
Breast Cancer
Interventions
Dato-DXd, Durvalumab, Paclitaxel, Nab-paclitaxel, Gemcitabine, Carboplatin, Pembrolizumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
625 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
66
States / cities
Daphne, Alabama • Springdale, Arkansas • Duarte, California + 57 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 21, 2026, 7:59 PM EDT
Completed Not applicable Interventional

Attention Training for Underserved Youth With Anxiety

NCT03028792
View directory record Official record
Conditions
Anxiety
Interventions
Attention Modification Program, Attention Control Condition
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
8 Years to 17 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
El Centro, California
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Oct 21, 2026, 7:59 PM EDT
Terminated Not applicable Interventional Results available

Feasibility and Acceptability of Stress Induction, Physiological Data Collection, and Mindfulness-Based Stress Reduction Among Combat Veterans With PTSD

NCT05938816
View directory record Official record
Conditions
Ptsd
Interventions
Mindfulness-Based Stress Reduction (MBSR), Health and Wellness Education (HWE)
Behavioral
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 85 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 5, 2024 · Synced Oct 21, 2026, 7:59 PM EDT
Active, not recruiting Phase 2 Interventional

4D-150 in Patients With Diabetic Macular Edema

NCT05930561
View directory record Official record
Conditions
Diabetic Macular Edema, Diabetic Retinopathy
Interventions
4D-150 IVT, Aflibercept IVT
Biological
Lead sponsor
4D Molecular Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
5
States / cities
Hagerstown, Maryland • Eugene, Oregon • Erie, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 21, 2026, 7:59 PM EDT
Completed Phase 3 Interventional Results available

Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study

NCT01877668
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Tofacitinib 5 mg BID, Tofacitinib 10 mg BID, Adalimumab, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
422 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
24
States / cities
Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2017 · Synced Oct 21, 2026, 7:59 PM EDT
Recruiting Not applicable Interventional

Exercise and Nutrition for Older Cancer Survivors and Their Support Person: The Vitality Study

NCT06623097
View directory record Official record
Conditions
Cancer Survivorship
Interventions
Supervised Exercise and Diet Program, Unsupervised Exercise and Diet Program
Behavioral
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
1,528 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
2
States / cities
Miami, Florida • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 21, 2026, 7:59 PM EDT
Recruiting Phase 2 Interventional

Psilocybin rTMS for Treatment Resistant Depression

NCT06132178
View directory record Official record
Conditions
Treatment Resistant Depression, MDD, Major Depressive Disorder, Recurrent Depression, Depression
Interventions
Psilocybin, Accelerated intermittent theta burst (aiTBS) rTMS treatment, Low-dose psilocybin, Sham Accelerated intermittent theta burst (aiTBS) rTMS treatment
Drug · Device
Lead sponsor
University of Texas at Austin
Other
Eligibility
22 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Oct 21, 2026, 7:59 PM EDT
Completed Not applicable Interventional

Prevention of Arthritis-Related Work Disability

NCT00000416
View directory record Official record
Conditions
Rheumatoid Arthritis, Systemic Lupus Erythematosus, Osteoarthritis, Knee, Ankylosing Spondylitis
Interventions
Rehabilitation counseling
Other
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
18 Years to 65 Years
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2001
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 26, 2017 · Synced Oct 21, 2026, 7:59 PM EDT
Completed Not applicable Interventional Results available

Crossover Trial for Nicotinamide Riboside in Subjective Cognitive Decline and Mild Cognitive Impairment

NCT04078178
View directory record Official record
Conditions
Cognition Disorders in Old Age, Mild Cognitive Impairment, Cognitive Decline
Interventions
Niagen, Placebo Comparator
Dietary Supplement
Lead sponsor
Steven E Arnold, MD
Other
Eligibility
60 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 29, 2024 · Synced Oct 21, 2026, 7:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Ambulatory ICU Study for Medically and Socially Complex Patients

NCT03224858
View directory record Official record
Conditions
Health Services, Comorbidity, Primary Health Care
Interventions
SUMMIT intervention, Enhanced usual care
Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 99 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 21, 2025 · Synced Oct 21, 2026, 7:59 PM EDT
Completed Phase 4 Interventional Results available

Citicoline for Alcohol Dependence

NCT02074735
View directory record Official record
Conditions
Alcohol Dependence
Interventions
Placebo, Citicoline
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 24, 2018 · Synced Oct 21, 2026, 7:59 PM EDT
Recruiting Phase 2 Interventional

Tocilizumab for Acute Chest Syndrome

NCT05640271
View directory record Official record
Conditions
Sickle Cell Disease, Acute Chest Syndrome
Interventions
Tocilizumab
Drug
Lead sponsor
University of Chicago
Other
Eligibility
12 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 21, 2026, 7:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Barriers to Physical Activity in People With Type 2 Diabetes

NCT01701570
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Placebo Attention Control, Supervised Exercise Training
Behavioral · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
50 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 14, 2022 · Synced Oct 21, 2026, 7:59 PM EDT
Terminated Phase 3 Interventional

Efficacy, Safety & Pharmacokinetic (PK) Study of HLD200 in Children Aged 4-5 Years With ADHD

NCT06431256
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
HLD200 methylphenidate hydrochloride capsules, Placebo HLD200 capsules
Drug
Lead sponsor
Ironshore Pharmaceuticals and Development, Inc
Other
Eligibility
4 Years to 5 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
13
States / cities
Dothan, Alabama • Anaheim, California • Jacksonville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Oct 21, 2026, 7:59 PM EDT
Recruiting Phase 3 Interventional

A Phase 3 Trial for Intravitreal Injection of 4D-150 in Adults With Diabetic Macular Edema (DME).

NCT07867080
View directory record Official record
Conditions
Diabetic Macular Edema (DME)
Interventions
4D-150 IVT (3x10^10 vg), EYELEA ® (aflibercept) Injection 2 mg (0.05mL)
Biological
Lead sponsor
4D Molecular Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
49
States / cities
Scottsdale, Arizona • Encino, California • Fullerton, California + 44 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 21, 2026, 7:59 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate ARD-101 in Adults With Obesity

NCT05121441
View directory record Official record
Conditions
Obesity
Interventions
ARD-101, Placebo
Drug
Lead sponsor
Aardvark Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 22, 2025 · Synced Oct 21, 2026, 7:59 PM EDT
Completed Phase 2 Interventional Results available

A 6-month Randomised, Double-blind, Open Arm Comparator, Phase IIb, With AZD9056, in Patients With Rheumatoid Arthritis (RA)

NCT00520572
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
AZD9056, Etanercept, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
8
States / cities
Aventura, Florida • Orlando, Florida • Sarasota, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Oct 21, 2026, 7:59 PM EDT
Not yet recruiting Not applicable Interventional

Study to Evaluate Xtressé Gummy Supplement in Men With Androgenic Alopecia

NCT07637071
View directory record Official record
Conditions
Androgenic Alopecia, Hair Loss/Baldness, Hair Thinning
Interventions
Xtressé Hair Growth Gummies, Placebo Comparator
Other · Dietary Supplement
Lead sponsor
Restore Biologics Holdings, Inc. dba Xtressé
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Maitland, Florida • Port Orange, Florida
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 21, 2026, 7:59 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Implementation of a ColoRectal Cancer Screening Tool in US Primary Care Practices - Usual Quality Improvement (10 Clinics) vs Normalization Process Theory-Participatory Learning in Action (10 Clinics)

NCT06682650
View directory record Official record
Conditions
Colorectal Carcinoma
Interventions
NPT-PLA, Usual Quality Improvement
Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
45 Years to 75 Years
Enrollment
2,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 21, 2026, 7:59 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effect of PDE5 Inhibition on Adipose Metabolism in Humans

NCT04684589
View directory record Official record
Conditions
Obesity
Interventions
Tadalafil 20 MG, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
19 Years to 50 Years
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 21, 2026, 7:59 PM EDT